c-MYC PROTACs for Selective Oncoprotein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies face challenges in effectively targeting the c-MYC oncogene for cancer treatment due to its 'undruggable' nature, as small molecules struggle to selectively inhibit c-MYC-driven cell proliferation and interfere with its binding to DNA.
Innovation Solution
Development of substituted heterocycles, such as pyrazoles, imidazoles, and triazoles, and proteolysis-targeting chimeric molecules (PROTACs) that specifically target c-MYC for degradation by utilizing a ligand to recruit an E3 ubiquitin ligase, thereby inducing protein degradation via ubiquitination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If small molecules are used to target c-MYC, then selectivity for c-MYC-driven cell proliferation can be improved, but the ability to effectively interfere with c-MYC binding to DNA deteriorates
Solution Approach 1:
The patent introduces PROTACs as intermediary molecules that mediate c-MYC degradation through the ubiquitin-proteasome system. The PROTAC consists of a c-MYC binding ligand, a linker, and an E3 ubiquitin ligase binder, which collectively enable selective c-MYC targeting and degradation without directly interfering with c-MYC-DNA binding. This intermediary approach resolves the contradiction by achieving selectivity through the PROTAC mechanism rather than direct small molecule inhibition.
Solution Approach 2:
The patent changes the fundamental parameter of c-MYC targeting from direct binding inhibition to protein degradation induction. By shifting from a static binding inhibition mechanism to a dynamic degradation mechanism via PROTACs, the system achieves effective c-MYC elimination while maintaining selectivity for c-MYC-expressing cells, thereby resolving the contradiction between selectivity and functional interference.
2Reliability
If PROTACs are used to induce c-MYC degradation, then effectiveness in targeting c-MYC can be improved, but complexity of the molecular structure deteriorates
Solution Approach 1:
The patent segments the PROTAC molecule into three distinct functional components: a c-MYC binding ligand (first moiety), a linker (second moiety), and an E3 ubiquitin ligase binder (third moiety). This segmentation allows each component to be optimized independently for its specific function while maintaining overall PROTAC effectiveness. The first moiety provides c-MYC selectivity, the linker provides structural flexibility, and the third moiety provides degradation capability, thereby achieving high reliability without excessive complexity.
Solution Approach 2:
The patent designs the PROTAC framework to be universally applicable for degrading various proteins by simply changing the ligand and E3 ligase binder components while maintaining the same basic tripartite structure. This multi-functionality approach allows the same PROTAC scaffold to target different proteins (e.g., c-MYC, BCL2, MYC) by substituting specific moieties, thereby achieving high reliability for multiple targets without proportionally increasing structural complexity.
3Measurement precision
If substituted heterocycles are used as c-MYC targeting agents, then selectivity for cancer cells can be improved, but difficulty in achieving protein degradation deteriorates
Solution Approach 1:
The patent uses substituted heterocycles (pyrazoles, imidazoles, triazoles) as intermediary ligands that selectively bind to c-MYC and serve as the foundation for PROTAC construction. These heterocyclic compounds provide the necessary selectivity for c-MYC-expressing cancer cells while serving as the first moiety in the PROTAC framework that enables subsequent protein degradation through E3 ligase recruitment. This intermediary approach resolves the contradiction by using the heterocycles as a bridge between selectivity and degradation capability.
Solution Approach 2:
The patent creates composite PROTAC molecules by combining substituted heterocyclic ligands with linkers and E3 ligase binders. This composite structure integrates the selectivity of the heterocyclic c-MYC binder with the degradation capability of the E3 ligase system. The composite nature of PROTACs allows the substituted heterocycles to provide cancer cell selectivity while the overall composite structure enables efficient protein degradation, thereby resolving the contradiction between selectivity and degradation effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The substituted heterocycles and PROTACs effectively inhibit c-MYC protein activity without causing significant DNA damage, selectively targeting cancer cells expressing c-MYC while sparing non-expressing cells, and demonstrate potential in treating various cancers.
Implementation Method 1
PROTACs include a ligand for recruiting an E3 ubiquitin ligase, a linker, and another ligand to bind with the protein targeted for degradation. Designed as such, PROTACs 'hijack' the E3 ubiquitin ligase to the protein which is targeted for protein degradation via ubiquitination
Data Source
AI summary
Disclosed are substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs). The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC. The disclosed PROTACs are shown to induce degradation of c-MYC protein. The substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs) disclosed, herein may be utilized as therapeutics for treating cancer and cell proliferative disorders.